Micron Biomedical collaborates with strategic partners to bring innovative microneedle patch products to market.
Micron’s technology offers key business advantages to pharmaceutical companies with actives under development or already on the market and seeking:
Increased competitive advantage
Improved immunogenicity (vaccines) or pharmacokinetics/dynamics (drugs)
Increased patient compliance
Patients staying on therapy longer
Increased market share
Product life cycle management
Extend life of vaccine/drug patent
Micron develops pharmaceutical products, based on its microneedle patch technology, that are designed to provide enhanced protective (vaccine) and therapeutic (drugs) effects, superior patient compliance, and simplified administration, distribution, and storage logistics.